Intranasal oestrogen cream for the prevention of epistaxis in patients with bleeding disorders.
Haemophilia (Impact Factor: 3.17). 01/2011; 17(1):164. DOI:10.1111/j.1365-2516.2010.02356.x
- The Laryngoscope 04/1982; 92(3):314-20. · 1.98 Impact Factor
- [show abstract] [hide abstract]
ABSTRACT: The combination of a progestogen and an estrogen (Enovid, Enovid E) has been used successfully in the management of nine patients with hereditary hemorrhagic telangiectasia (HHT) and severe epistaxis: Such therapy was instituted when epistaxis was severe and only after other therapeutic measures had failed. Seven of our patients required the 5-mg tablet (Enovid) to achieve a satisfactory clinical result; two patients received the 2.5-mg preparation (Enovid E). The eight women received cyclic therapy; the man received therapy without interruption. Because of the possibility of serious adverse effects from the drugs, it is required that each patient receive a complete medical evaluation prior to therapy and at frequent intervals while receiving therapy. Enovid therapy for HHT is not recommended for the patient with mild bleeding that can be controlled by conventional therapy.Archives of otolaryngology (Chicago, Ill.: 1960) 04/1977; 103(3):148-51.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.